The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy.
| dc.contributor.author | Stewart, Alan L | |
| dc.contributor.author | Margison, Jennifer M | |
| dc.contributor.author | Wilkinson, Peter M | |
| dc.contributor.author | Lucas, S | |
| dc.date.accessioned | 2010-12-02T17:03:39Z | |
| dc.date.available | 2010-12-02T17:03:39Z | |
| dc.date.issued | 1985 | |
| dc.identifier.citation | The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy. 1985, 14 (2):165-7 Cancer Chemother Pharmacol | en |
| dc.identifier.issn | 0344-5704 | |
| dc.identifier.pmid | 3971482 | |
| dc.identifier.doi | 10.1007/BF00434358 | |
| dc.identifier.uri | http://hdl.handle.net/10541/116972 | |
| dc.description.abstract | An unambiguous and specific HPLC assay was used to determine the pharmacokinetics of 7-hydroxymethotrexate (7-OHMTX) following the administration of moderate-dose methotrexate (MTX) 100 mg X m-2 to 37 patients with advanced head and neck cancer. There was marked interpatient variation but patient exposure to 7-OHMTX was considerable. There was, however, no correlation between the amount of 7-OHMTX produced and either tumour response or patient toxicity. | |
| dc.language.iso | en | en |
| dc.subject | Head and Neck Cancer | en |
| dc.subject.mesh | Chromatography, High Pressure Liquid | |
| dc.subject.mesh | Head and Neck Neoplasms | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Kinetics | |
| dc.subject.mesh | Methotrexate | |
| dc.title | The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy. | en |
| dc.type | Article | en |
| dc.contributor.department | Department of Clinical Pharmacology, CHristie Hospital & Holt Radium Institute, Withington, Manchester, M20 9BX, England | en |
| dc.identifier.journal | Cancer Chemotherapy and Pharmacology | en |
| html.description.abstract | An unambiguous and specific HPLC assay was used to determine the pharmacokinetics of 7-hydroxymethotrexate (7-OHMTX) following the administration of moderate-dose methotrexate (MTX) 100 mg X m-2 to 37 patients with advanced head and neck cancer. There was marked interpatient variation but patient exposure to 7-OHMTX was considerable. There was, however, no correlation between the amount of 7-OHMTX produced and either tumour response or patient toxicity. |